Log in

Relevant bibliographies by topics / Antibody Dependent Enhancement / Journal articles

To see the other types of publications on this topic, follow the link: Antibody Dependent Enhancement.

Journal articles on the topic 'Antibody Dependent Enhancement'

Author: Grafiati

Published: 4 June 2021

Last updated: 4 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Antibody Dependent Enhancement.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Wen, Jieqi, Yifan Cheng, Rongsong Ling, Yarong Dai, Boxuan Huang, Wenjie Huang, Siyan Zhang, and Yizhou Jiang. "Antibody-dependent enhancement of coronavirus." International Journal of Infectious Diseases 100 (November 2020): 483–89. http://dx.doi.org/10.1016/j.ijid.2020.09.015.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Thomas, Sandra, Jade B. Redfern, Brett A. Lidbury, and Suresh Mahalingam. "Antibody-dependent enhancement and vaccine development." Expert Review of Vaccines 5, no. 4 (August 2006): 409–12. http://dx.doi.org/10.1586/14760584.5.4.409.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Gras, G., T. Strub, D. Dormont, Jacques Homsy, Masatoshi Tateno, and JayA Levy. "ANTIBODY-DEPENDENT ENHANCEMENT OF HIV INFECTION." Lancet 331, no. 8597 (June 1988): 1285–86. http://dx.doi.org/10.1016/s0140-6736(88)92106-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Burke, Donald S., and Srisakul Kliks. "Antibody‐Dependent Enhancement in Dengue Virus Infections." Journal of Infectious Diseases 193, no. 4 (February 15, 2006): 601–3. http://dx.doi.org/10.1086/499282.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Nakayama, Eri, Daisuke Tomabechi, Keita Matsuno, Noriko Kishida, Reiko Yoshida, Heinz Feldmann, and Ayato Takada. "Antibody-Dependent Enhancement of Marburg Virus Infection." Journal of Infectious Diseases 204, suppl_3 (November 2011): S978—S985. http://dx.doi.org/10.1093/infdis/jir334.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Kurane, I., B. J. Mady, and F. A. Ennis. "Antibody-dependent enhancement of dengue virus infection." Reviews in Medical Virology 1, no. 4 (December 1991): 211–21. http://dx.doi.org/10.1002/rmv.1980010405.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Takada, Ayato, Heinz Feldmann, Thomas G. Ksiazek, and Yoshihiro Kawaoka. "Antibody-Dependent Enhancement of Ebola Virus Infection." Journal of Virology 77, no. 13 (July 1, 2003): 7539–44. http://dx.doi.org/10.1128/jvi.77.13.7539-7544.2003.

Full text

Abstract:

ABSTRACT Most strains of Ebola virus cause a rapidly fatal hemorrhagic disease in humans, yet there are still no biologic explanations that adequately account for the extreme virulence of these emerging pathogens. Here we show that Ebola Zaire virus infection in humans induces antibodies that enhance viral infectivity. Plasma or serum from convalescing patients enhanced the infection of primate kidney cells by the Zaire virus, and this enhancement was mediated by antibodies to the viral glycoprotein and by complement component C1q. Our results suggest a novel mechanism of antibody-dependent enhancement of Ebola virus infection, one that would account for the dire outcome of Ebola outbreaks in human populations.

APA, Harvard, Vancouver, ISO, and other styles

8

Meyer, Keith, Malika Ait-Goughoulte, Zhen-Yong Keck, Steven Foung, and Ranjit Ray. "Antibody-Dependent Enhancement of Hepatitis C Virus Infection." Journal of Virology 82, no. 5 (December 19, 2007): 2140–49. http://dx.doi.org/10.1128/jvi.01867-07.

Full text

Abstract:

ABSTRACT Hepatitis C virus (HCV) often causes a persistent infection associated with hypergammaglobulinemia, high levels of antiviral antibody and circulating immune complexes, and immune complex disease. We previously reported that only a limited neutralizing activity to vesicular stomatitis virus or HCV pseudotype is generated in animals immunized with recombinant HCV envelope proteins and chronically infected HCV patient sera. Interestingly, when some of these neutralizing sera were diluted into a range of concentrations below those that reduced virus plaque number, an increase in pseudotype plaque formation was observed. Purified HCV E2-specific human monoclonal antibodies were used to further verify the specificity of this enhancement, and one- to twofold increases were apparent on permissive Huh-7 cells. The enhancement of HCV pseudotype titer could be inhibited by the addition of a Fc-specific anti-human immunoglobulin G Fab fragment to the virus-antibody mixture prior to infection. Treatment of cells with antibody to Fc receptor I (FcRI) or FcRII, but not FcRIII, also led to an inhibition of pseudotype titer enhancement in an additive manner. Human lymphoblastoid cell line (Raji), a poor host for HCV pseudotype infection, exhibited a four- to sixfold enhancement of pseudotype-mediated cell death upon incubation with antibody at nonneutralizing concentrations. A similar enhancement of cell culture-grown HCV infectivity by a human monoclonal antibody was also observed. Taken together, antibodies to viral epitopes enhancing HCV infection need to be taken into consideration for pathogenesis and in the development of an effective vaccine.

APA, Harvard, Vancouver, ISO, and other styles

9

Billings, Lora, Amy Fiorillo, and Ira B. Schwartz. "Vaccinations in disease models with antibody-dependent enhancement." Mathematical Biosciences 211, no. 2 (February 2008): 265–81. http://dx.doi.org/10.1016/j.mbs.2007.08.004.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Eaton, Heather E., Emily Penny, and Craig R. Brunetti. "Antibody dependent enhancement of frog virus 3 infection." Virology Journal 7, no. 1 (2010): 41. http://dx.doi.org/10.1186/1743-422x-7-41.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Giordano, Mirta, and Marina S. Palermo. "Melatonin-induced enhancement of antibody-dependent cellular cytotoxicity." Journal of Pineal Research 10, no. 3 (April 1991): 117–21. http://dx.doi.org/10.1111/j.1600-079x.1991.tb00827.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Tirado, Sol M. Cancel, and Kyoung-Jin Yoon. "Antibody-Dependent Enhancement of Virus Infection and Disease." Viral Immunology 16, no. 1 (April 2003): 69–86. http://dx.doi.org/10.1089/088282403763635465.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Katzelnick, Leah C., Lionel Gresh, M. Elizabeth Halloran, Juan Carlos Mercado, Guillermina Kuan, Aubree Gordon, Angel Balmaseda, and Eva Harris. "Antibody-dependent enhancement of severe dengue disease in humans." Science 358, no. 6365 (November 2, 2017): 929–32. http://dx.doi.org/10.1126/science.aan6836.

Full text

Abstract:

For dengue viruses 1 to 4 (DENV1-4), a specific range of antibody titer has been shown to enhance viral replication in vitro and severe disease in animal models. Although suspected, such antibody-dependent enhancement of severe disease has not been shown to occur in humans. Using multiple statistical approaches to study a long-term pediatric cohort in Nicaragua, we show that risk of severe dengue disease is highest within a narrow range of preexisting anti-DENV antibody titers. By contrast, we observe protection from all symptomatic dengue disease at high antibody titers. Thus, immune correlates of severe dengue must be evaluated separately from correlates of protection against symptomatic disease. These results have implications for studies of dengue pathogenesis and for vaccine development, because enhancement, not just lack of protection, is of concern.

APA, Harvard, Vancouver, ISO, and other styles

14

Wang, Xiaoyu, Yong-Qiang Deng, Dong Yang, Yun Xiao, Hui Zhao, Qing-Gong Nian, Xurong Xu, Xiao-Feng Li, Ruikang Tang, and Cheng-Feng Qin. "Biomimetic inorganic camouflage circumvents antibody-dependent enhancement of infection." Chemical Science 8, no. 12 (2017): 8240–46. http://dx.doi.org/10.1039/c7sc03868b.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Gorlani, Andrea, and Donald Forthal. "Antibody-Dependent Enhancement and the Risk of HIV Infection." Current HIV Research 11, no. 5 (November 2013): 421–26. http://dx.doi.org/10.2174/1570162x113116660062.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Billings, Lora, Ira B. Schwartz, Leah B. Shaw, Marie McCrary, Donald S. Burke, and Derek A. T. Cummings. "Instabilities in multiserotype disease models with antibody-dependent enhancement." Journal of Theoretical Biology 246, no. 1 (May 2007): 18–27. http://dx.doi.org/10.1016/j.jtbi.2006.12.023.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Mahalingam, Surendran, and Brett A. Lidbury. "Antibody-dependent enhancement of infection: bacteria do it too." Trends in Immunology 24, no. 9 (September 2003): 465–67. http://dx.doi.org/10.1016/s1471-4906(03)00210-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Taylor, Adam, Suan-Sin Foo, Roberto Bruzzone, Luan Vu Dinh, Nicholas J. C. King, and Suresh Mahalingam. "Fc receptors in antibody-dependent enhancement of viral infections." Immunological Reviews 268, no. 1 (October 26, 2015): 340–64. http://dx.doi.org/10.1111/imr.12367.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Phillpotts, R. J., J. R. Stephenson, and J. S. Porterfield. "Antibody-dependent Enhancement of Tick-borne Encephalitis Virus Infectivity." Journal of General Virology 66, no. 8 (August 1, 1985): 1831–37. http://dx.doi.org/10.1099/0022-1317-66-8-1831.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Soneja, Manish, Rohit Kumar, Nitin Gupta, Parul Kodan, Ankit Mittal, and Naveet Wig. "Is there antibody-dependent enhancement in SARS Coronavirus 2?" Journal of Family Medicine and Primary Care 9, no. 5 (2020): 2589. http://dx.doi.org/10.4103/jfmpc.jfmpc_540_20.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Wang, Shih-Min, I. Chun Chen, Ling-Yao Su, Kao-Jean Huang, Huan-Yao Lei, and Ching-Chuan Liu. "Enterovirus 71 Infection of Monocytes with Antibody-Dependent Enhancement." Clinical and Vaccine Immunology 17, no. 10 (August 4, 2010): 1517–23. http://dx.doi.org/10.1128/cvi.00108-10.

Full text

Abstract:

ABSTRACT Enterovirus (EV) is an RNA virus that has circulated with different serotypes and genotypes worldwide. Enterovirus 71 (EV71) is a major neurotropic virus that causes severe brain stem encephalitis (BE) in infants and young children. The most vulnerable age for fatal infection is 6 to 11 months. This is associated with the coincident decline in maternal antibodies. The current report describes our finding that EV71 can infect human peripheral blood monocytes. We were able to show that EV71 infection is enhanced in the monocytic cell line THP-1 by the presence of subneutralizing concentrations of anti-EV71 antibodies. We also found that antibody-dependent enhancement (ADE) is mediated in part by Fcγ receptors. These observations support the concept that ADE augments the infectivity of EV71 for human monocytes and contributes to the age-dependent pathogenesis of EV71-induced disease. The ADE phenomenon must be considered during the development of an EV71 vaccine.

APA, Harvard, Vancouver, ISO, and other styles

22

Bernth-Jensen, Jens Magnus, Bjarne Kuno Møller, Steffen Thiel, and Anette Tarp Hansen. "Antibody Dependent Enhancement of Infections after High Dose Chemotherapy." Blood 134, Supplement_1 (November 13, 2019): 1047. http://dx.doi.org/10.1182/blood-2019-122236.

Full text

Abstract:

Background: High dose chemotherapy (HDT) burdens patients with a high risk of serious infections while neutropenic. The role of host antibodies as risk factors for infections is unclear. Our aim was to investigate if pre-HDT levels of IgG antibodies against terminal Galα3Gal (anti-αGal) predict infections. Anti-αGal is reported to be the most abundant antibody in human plasma and is able to recognize most sepsis-causing Gram-negative bacteria. The antibody exerts poor complement activation, which promotes pathogen survival by blocking access of more effective complement activators. This may be particularly problematic in neutropenic patients. Thus, we hypothesized that patients with high anti-αGal serum concentrations are particularly prone to suffer infections following HDT. Methods: We conducted a clinical cohort study on patients ≥16 years receiving HDT with autologous stem cell transplantation for myelomatosis (MM) or non-Hodgkin lymphoma (NHL) at Department of Hematology, Aarhus University Hospital, Denmark from 25 November 2009 through 26 June 2015. Of eligible patients (N=308), we excluded previous transplanted (N=14), those without a pre-HDT serum sample available for anti-αGal quantification (N=115), and recipients of plasma transfusion/IgG substitutions within 90 days before the pre-HDT serum sample and until end of follow-up (N=9). All included received prophylactic antimicrobial therapy (levofloxacin and fluconazol) and filgrastim. Serum anti-αGal was quantified using an in-house Time-resolved Immuno-Fluoremetric Assay. We ascertained infectious episodes within 30 days following the date of autologous stem cell re-infusion through review of all medical charts and data retrieval from the laboratory information systems, blinded for anti-αGal concentrations. Infectious episodes were defined as fever (≥38.5°C) or hypothermia (<36°C) prompting antibiotic treatment and CRP > 21 mg/L preceded by at least 24 hours without any of these. We used a Cox proportional hazards model to investigate the association between anti-αGal concentrations and risk of infection, with adjustment for total plasma IgG concentrations, ABO blood group, comorbidity, and underlying disease (MM or NHL) in the adjusted hazard ratios (HR). Optimum cutoff for dichotomizing was determined from ROC analysis applying Youden´s J statistic and groups were compared by Kaplan-Meier method. Results: We included 170 patients (MM, 55%; males, 58%; median age 62 years). Severe neutropenia was transient in all, with blood neutrophils increasing to above 500/µL on median day 11 (range 8-18). We identified one infectious episode in 103 patients (61%) and two episodes in six (3.5%) patients. The infectious episodes began during severe neutropenia in 92% of the patients. The infection types were fever of unknown origin (FUO) (72%), pneumonia (19%), catheter related (4.3%), typhlitis (1.7%), C. difficile colitis (1.7%), and hypothermia of unknown origin (0.87%). None died from infections. Pre-HDT serum was collected on median day -31 (range -142- -16). Anti-αGal was detectable in all but one sample, averaging 0.51 mg/dL (range: 0.016-12). Overall, anti-αGal concentrations predicted infectious episodes (all types), crude HR 1.2 (95% confidence interval (CI) 1.1-1.4), adjusted HR 1.1 (95% CI: 1.0-1.3). Using anti-αGal at 1.3 mg/dL as cut-off, we identified that patients with higher concentrations (N=41) experienced considerably increased risk of infectious episodes (crude estimates): all types, HR 1.7 (95% CI: 1.3-3.2); FUO, HR 2.0 (95%CI: 1.5-4.5); and pneumonia HR 2.1 (95%CI: 0.83-8.7). Discussion: We found that high anti-αGal serum concentrations predict an increased risk of infection after HDT. These findings support that anti-αGal may critically enhance pathogen-survival in the neutropenic host. Studies of other cohorts and mechanistic studies are required. Our findings may pave the way for future optimized risk stratification and therapeutic measures. Disclosures No relevant conflicts of interest to declare.

APA, Harvard, Vancouver, ISO, and other styles

23

Yager, Eric J. "Antibody-dependent enhancement and COVID-19: Moving toward acquittal." Clinical Immunology 217 (August 2020): 108496. http://dx.doi.org/10.1016/j.clim.2020.108496.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Guzman, Maria G., and Susana Vazquez. "The Complexity of Antibody-Dependent Enhancement of Dengue Virus Infection." Viruses 2, no. 12 (December 8, 2010): 2649–62. http://dx.doi.org/10.3390/v2122649.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Robinson, W. Edward, DavidC Montefiori, and WilliamM Mitchell. "ANTIBODY-DEPENDENT ENHANCEMENT OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTION." Lancet 331, no. 8589 (April 1988): 790–94. http://dx.doi.org/10.1016/s0140-6736(88)91657-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Lee, Wen Shi, Adam K. Wheatley, Stephen J. Kent, and Brandon J. DeKosky. "Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies." Nature Microbiology 5, no. 10 (September 9, 2020): 1185–91. http://dx.doi.org/10.1038/s41564-020-00789-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Takada, Ayato, Hideki Ebihara, Heinz Feldmann, Thomas W. Geisbert, and Yoshihiro Kawaoka. "Epitopes Required for Antibody‐Dependent Enhancement of Ebola Virus Infection." Journal of Infectious Diseases 196, s2 (November 15, 2007): S347—S356. http://dx.doi.org/10.1086/520581.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Chan, Ying Kai, I.-Chueh Huang, and Michael Farzan. "IFITM Proteins Restrict Antibody-Dependent Enhancement of Dengue Virus Infection." PLoS ONE 7, no. 3 (March 30, 2012): e34508. http://dx.doi.org/10.1371/journal.pone.0034508.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

NAGASHIMA, Hiroaki, and Yasuhiko MASUHO. "Enhancement of Antibody-dependent Cellular Cytotoxicity by Tandem Fc Multimerization." YAKUGAKU ZASSHI 130, no. 1 (January 1, 2010): 49–54. http://dx.doi.org/10.1248/yakushi.130.49.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Bournazos, Stylianos, Aaron Gupta, and Jeffrey V. Ravetch. "The role of IgG Fc receptors in antibody-dependent enhancement." Nature Reviews Immunology 20, no. 10 (August 11, 2020): 633–43. http://dx.doi.org/10.1038/s41577-020-00410-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Wang-Lin, Shun Xin, Ruth Olson, Janet M. Beanan, Ulrike MacDonald, Thomas A. Russo, and Joseph P. Balthasar. "Antibody Dependent Enhancement ofAcinetobacter baumanniiInfection in a Mouse Pneumonia Model." Journal of Pharmacology and Experimental Therapeutics 368, no. 3 (January 3, 2019): 475–89. http://dx.doi.org/10.1124/jpet.118.253617.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Yao, J. S., H. Kariwa, I. Takashima, K. Yoshimatsu, J. Arikawa, and N. Hashimoto. "Antibody-dependent enhancement of hantavirus infection in macrophage cell lines." Archives of Virology 122, no. 1-2 (March 1992): 107–18. http://dx.doi.org/10.1007/bf01321121.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Mitchell, William M., W. Edward Robinson, and David C. Montefiori. "Antibody-dependent enhancement of viral infectivity. I. An ineffective response." Infectious Diseases Newsletter 7, no. 8 (August 1988): 59–60. http://dx.doi.org/10.1016/0278-2316(88)90053-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Nicholson, Cindo O., Joshua M. Costin, Dawne K. Rowe, Li Lin, Ekachai Jenwitheesuk, Ram Samudrala, Sharon Isern, and Scott F. Michael. "Viral entry inhibitors block dengue antibody-dependent enhancement in vitro." Antiviral Research 89, no. 1 (January 2011): 71–74. http://dx.doi.org/10.1016/j.antiviral.2010.11.008.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Tawar, Shabeena, Parnika Chandola, and Sougat Ray. "Is antibody-dependent enhancement a cause for COVID Vaccine hesitancy." Journal of Marine Medical Society 23, no. 1 (2021): 107. http://dx.doi.org/10.4103/jmms.jmms_93_21.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Corapi, W. V., C. W. Olsen, and F. W. Scott. "Monoclonal antibody analysis of neutralization and antibody-dependent enhancement of feline infectious peritonitis virus." Journal of Virology 66, no. 11 (1992): 6695–705. http://dx.doi.org/10.1128/jvi.66.11.6695-6705.1992.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

A. Desheva, Yu, A. S. Mamontov, and P. G. Nazarov. "Contribution of antibody-dependent enhancement to the pathogenesis of coronavirus infections." AIMS Allergy and Immunology 4, no. 3 (2020): 50–59. http://dx.doi.org/10.3934/allergy.2020005.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Ghiasi, Homayon, Guey-Chuen Perng, Anthony B. Nesburn, and Steven L. Wechsler. "Antibody-dependent enhancement of HSV-1 infection by anti-gK sera." Virus Research 68, no. 2 (July 2000): 137–44. http://dx.doi.org/10.1016/s0168-1702(00)00165-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Cardosa, M. J. "DENGUE VIRUS ISOLATION BY ANTIBODY-DEPENDENT ENHANCEMENT OF INFECTIVITY IN MACROPHAGES." Lancet 329, no. 8526 (January 1987): 193–94. http://dx.doi.org/10.1016/s0140-6736(87)90005-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Suhrbier, Andreas, and May La Linn. "Suppression of antiviral responses by antibody-dependent enhancement of macrophage infection." Trends in Immunology 24, no. 4 (April 2003): 165–68. http://dx.doi.org/10.1016/s1471-4906(03)00065-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Arvin, Ann M., Katja Fink, Michael A. Schmid, Andrea Cathcart, Roberto Spreafico, Colin Havenar-Daughton, Antonio Lanzavecchia, Davide Corti, and Herbert W. Virgin. "A perspective on potential antibody-dependent enhancement of SARS-CoV-2." Nature 584, no. 7821 (July 13, 2020): 353–63. http://dx.doi.org/10.1038/s41586-020-2538-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Rao, Gautham K., Rodney A. Prell, Steven T. Laing, Stefanie C. M. Burleson, Allen Nguyen, Jacqueline M. McBride, Crystal Zhang, Daniel Sheinson, and Wendy G. Halpern. "In Vivo Assessment of Antibody-Dependent Enhancement of Influenza B Infection." Toxicological Sciences 169, no. 2 (February 22, 2019): 409–21. http://dx.doi.org/10.1093/toxsci/kfz053.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Gould, E. A., and A. Buckley. "Antibody-dependent Enhancement of Yellow Fever and Japanese Encephalitis Virus Neurovirulence." Journal of General Virology 70, no. 6 (June 1, 1989): 1605–8. http://dx.doi.org/10.1099/0022-1317-70-6-1605.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Morens, D. M. "Antibody-Dependent Enhancement of Infection and the Pathogenesis of Viral Disease." Clinical Infectious Diseases 19, no. 3 (September 1, 1994): 500–512. http://dx.doi.org/10.1093/clinids/19.3.500.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Takada, Ayato, and Yoshihiro Kawaoka. "Antibody-dependent enhancement of viral infection: molecular mechanisms andin vivo implications." Reviews in Medical Virology 13, no. 6 (2003): 387–98. http://dx.doi.org/10.1002/rmv.405.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

FLIEGER, DIMITRI, ULRICH SPENGLER, IMKE BEIER, ROLF KLEINSCHMIDT, ANJA HOFF, MICHAEL VARVENNE, TILMAN SAUERBRUCH, and INGO SCHMIDT-WOLF. "Enhancement of Antibody Dependent Cellular Cytotoxicity (ADCC) by Combination of Cytokines." Hybridoma 18, no. 1 (February 1999): 63–68. http://dx.doi.org/10.1089/hyb.1999.18.63.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Zoellner, B., H. H. Feucht, and R. Laufs. "Role of proteases as cofactors for antibody-dependent enhancement of HIV." AIDS 6, no. 8 (August 1992): 887. http://dx.doi.org/10.1097/00002030-199208000-00023.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Wallace, M. J., D. W. Smith, A. K. Broom, J. S. Mackenzie, R. A. Hall, G. R. Shellam, and P. C. McMinn. "Antibody-dependent enhancement of Murray Valley encephalitis virus virulence in mice." Journal of General Virology 84, no. 7 (July 1, 2003): 1723–28. http://dx.doi.org/10.1099/vir.0.18980-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Cummings, D. A. T., I. B. Schwartz, L. Billings, L. B. Shaw, and D. S. Burke. "Dynamic effects of antibody-dependent enhancement on the fitness of viruses." Proceedings of the National Academy of Sciences 102, no. 42 (October 10, 2005): 15259–64. http://dx.doi.org/10.1073/pnas.0507320102.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Kuczera, Diogo, João Paulo Assolini, Fernanda Tomiotto-Pellissier, Wander Rogério Pavanelli, and Guilherme Ferreira Silveira. "Highlights for Dengue Immunopathogenesis: Antibody-Dependent Enhancement, Cytokine Storm, and Beyond." Journal of Interferon & Cytokine Research 38, no. 2 (February 2018): 69–80. http://dx.doi.org/10.1089/jir.2017.0037.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!